Myriad Genetics Teams Up with Access Health® to Educate the Public about Hereditary Cancer and Genetic Testing

SALT LAKE CITY, March 21, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, and Access Health®, an educational program focused on health and wellness, today announced that they will air an educational program on hereditary cancer that will appear on Lifetime®. The program, titled “Hereditary Cancer Risk Assessment and Testing: The Answer Is in Your DNA,” will run on Wednesday, March 30, 2016 7:30 am (ET/PT) and again on Wednesday, April 6, 2016 7:30 am (ET/PT).

Individuals diagnosed with hereditary cancer syndromes such as Lynch Syndrome and Hereditary Breast and Ovarian Cancer Syndrome are at significantly higher risk of developing cancer than the general population. In this special episode of Access Health, viewers will hear from experts in the field of hereditary cancer, including certified genetic counselor Marianne Lotito and Angelina Jolie's breast surgeon, Dr. Kristi Funk.

With regard to the show, Dr. Kristi Funk, M.D., said, “I am excited to be a part of this special episode of Access Health which educates individuals on the importance of cancer family history and the role genetic testing plays in understanding both individual cancer risk and related medical management options.”

The program discusses the value of knowing personal and family cancer history, follows the inspirational journeys of two families affected by hereditary cancer and highlights how genetic testing positively impacted their lives and that of their families. The program also discusses hereditary cancer resources, including Myriad’s Hereditary Cancer Quiz that helps individuals learn about their hereditary cancer risk. This quiz is an online resource that helps individuals evaluate their personal/family cancer history and whether they may be candidates for genetic testing. It then generates a family history overview that can be shared with healthcare providers.

“We are very excited to support this Lifetime program, which is a broad, powerful resource for people seeking answers on a variety of important health questions related to genetic testing and cancer,” said Bret Christensen, general manager, Preventive Care, Myriad Genetic Laboratories. “Our goal is to educate the public and to empower all Americans to live healthier lives. The Hereditary Cancer Quiz is a quick way for people to determine if they have any red flags for hereditary cancer.”

To take the Hereditary Cancer Quiz, please visit

About Myriad Genetics
For more than 25 years, Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website:

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G

Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to information to be presented in the Access Health program, titled “Hereditary Cancer Risk Assessment and Testing: The Answer Is in Your DNA"; data on the causes and risks associated with hereditary cancer syndromes; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2015, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Media Contact: Ron Rogers (908) 285-0248 Investor Contact: Scott Gleason (801) 584-1143

Source:Myriad Genetics, Inc.